Login to Your Account

Early HCV Study Data 'Speaks Volumes,' Boosts Vertex Stock

By Randall Osborne

Wednesday, May 11, 2005
Positive interim Phase Ib data with VX-950, its oral protease inhibitor for hepatitis C, was enough to send Vertex Pharmaceuticals Inc. on an upward ride that left the company's shares 19.8 percent greater by the end of the day. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription